Sign up to save your podcasts
Or
Share Episode 13: Sarepta
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 13: Sarepta
Send us a text
DISCLAIMER: This is a consistently changing situation. The episode was recorded approximately 4 PM EDT Monday, July 21, 2025. As of 7.40 PM EDT Monday, July 21, 2025 (Source: Sarepta), "Sarepta Therapeutics notified the U.S. FDA of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025."
🎙️ When Hope Collides with Risk: Sarepta’s Gene Therapy Crisis
In this episode of Petri Dish Perspectives, Manead goes off-script to unpack one of the hottest biotech stories in the headlines today: the unraveling of Sarepta Therapeutics.
What began in a small Oregon lab in 1980 as Antivirals Inc. evolved into Sarepta, a pioneer in the fight against Duchenne muscular dystrophy (DMD). From early exon-skipping breakthroughs to the dazzling promise of its gene therapy, Elevidys, Sarepta has long been a symbol of hope for families facing an otherwise devastating disease.
But in 2025, that hope hit a hard wall: patient deaths, regulatory clashes, and a growing crisis that’s shaking confidence in gene therapy as a whole. In under 30 minutes, Manead breaks down Sarepta’s 40-year journey, the science, the promise, the standoff with the FDA and what this turning point means for the future of genetic medicine.
This isn’t just another biotech update, it’s a raw look at what happens when cutting-edge hope meets the harsh edge of reality.
Grab your coffee or tea, hit play, and stay curious.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #GeneTherapy #Sarepta #DMD #FDA #RareDisease #PetriDishPerspectives #BiotechUnleashed
Support the show
© 2025 Petri Dish Perspectives LLC. All rights reserved.
View all episodes
By Manead KhinSend us a text
DISCLAIMER: This is a consistently changing situation. The episode was recorded approximately 4 PM EDT Monday, July 21, 2025. As of 7.40 PM EDT Monday, July 21, 2025 (Source: Sarepta), "Sarepta Therapeutics notified the U.S. FDA of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025."
🎙️ When Hope Collides with Risk: Sarepta’s Gene Therapy Crisis
In this episode of Petri Dish Perspectives, Manead goes off-script to unpack one of the hottest biotech stories in the headlines today: the unraveling of Sarepta Therapeutics.
What began in a small Oregon lab in 1980 as Antivirals Inc. evolved into Sarepta, a pioneer in the fight against Duchenne muscular dystrophy (DMD). From early exon-skipping breakthroughs to the dazzling promise of its gene therapy, Elevidys, Sarepta has long been a symbol of hope for families facing an otherwise devastating disease.
But in 2025, that hope hit a hard wall: patient deaths, regulatory clashes, and a growing crisis that’s shaking confidence in gene therapy as a whole. In under 30 minutes, Manead breaks down Sarepta’s 40-year journey, the science, the promise, the standoff with the FDA and what this turning point means for the future of genetic medicine.
This isn’t just another biotech update, it’s a raw look at what happens when cutting-edge hope meets the harsh edge of reality.
Grab your coffee or tea, hit play, and stay curious.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #GeneTherapy #Sarepta #DMD #FDA #RareDisease #PetriDishPerspectives #BiotechUnleashed
Support the show
© 2025 Petri Dish Perspectives LLC. All rights reserved.